About Arialys Therapeutics
Arialys Therapeutics is a private company based in LA Jolla, California, incorporated in 2021 in Delaware. It has reported $29,133,354 raised in two offerings on Form D since December 2022. Its chief executive is Peter Flynn, Ph.D..
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jun 13, 2025 | Jul 1, 2025 | $14,800,017of $24.8M target | 7 | $2.1M | EquityRule 506(b) | Form D ↗ |
| Nov 18, 2022 | Dec 2, 2022 | $14,333,337of $55.0M target | 6 | $2.3M | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $29,133,354 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Arialys Therapeutics's Form D filed Jul 1, 2025.
JD
Jay Lichter, Ph.D.
Director
PD
Peter Flynn, Ph.D.
Chief Executive Officer and director
BH
EH
Ed Hurwitz
Director
AD
Ashish Xavier, Ph.D.
Director
Earlier filings also listed Tighe Reardon (executive officer, last listed Dec 2022).